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OBJECTIVES We studied the antithrombotic effect of coating glass, collagen and metal stent surfaces with
bovine serum albumin (BSA) covalently modified to carry S-NO functional groups denoted
(pS-NO-BSA).
METHODS Video-enhanced light microscopy was used to visualize canine blood platelet adhesion and
aggregation in a parallel plate glass chamber. Platelet adhesion was observed for 60 min on
glass, glass coated with BSA, glass coated with pS-NO-BSA, collagen I (CO) surface, CO
coated with BSA and CO coated with pS-NO-BSA. We also coated Palmaz-Shatz (P-S)
stents with pS-NO-BSA. Coated and uncoated stents were then immersed in porcine
platelet-rich plasma for two min and the platelet cyclic GMP level was measured. In six
anesthetized pigs, coated and uncoated stents were placed in the carotid arteries and
[111In]-labeled platelets were circulated for 2 h. The stented arteries were then removed and
placed in a gamma well counter.
RESULTS There was significantly less platelet attachment, adhesion and aggregation on the pS-NO-
BSA coated surfaces compared with the BSA coated and uncoated surfaces. The pS-NO-
BSA coating increased the platelet cGMP levels to 5.9 6 0.7 pmoles/108 platelets compared
with 2.7 6 0.9 pmoles/108 platelets for control (p , 0.01). The average gamma ray count
from [111In]-labeled platelets that attached to the coated stents was 90,000 6 42,000/min
and 435,000 6 290,000/min for the uncoated stents (p , 0.01).
CONCLUSIONS The pS-NO-BSA coating of thrombogenic surfaces reduces platelet adhesion and aggrega-
tion, possibly by increasing the platelet cGMP. This inhibitory effect appears to be a
consequence of the direct antiplatelet actions of NO combined with the antiadhesive
properties of albumin. (J Am Coll Cardiol 1999;33:1408–14) © 1999 by the American
College of Cardiology
Endothelium-derived relaxing factor (EDRF), which is
closely related to nitric oxide (NO), is one of the primary
antithrombotic factors produced by the vascular endothe-
lium (1). NO (2,3) and NO-donating compounds, such as
nitroglycerin (4) and sodium nitroprusside (5) given intra-
venously, were found to inhibit platelet interactions with
damaged and stenosed canine coronary arteries. Endothelial
NO inhibits both platelet adhesion and platelet aggregation.
Nitric oxide also relaxes vascular smooth muscle cells (2)
and inhibits vascular smooth muscle cell proliferation (6).
Removal of the endothelium by plaque rupture or acute
vascular damage is a potent stimulus for thrombosis and
neointimal hyperplasia which are believed to be key events
in atherogenesis and restenosis after angioplasty.
Albumin is often used for coating vascular grafts to
passivate surfaces in contact with blood and thus minimize
surface-induced platelet activation (7,8). Albumin reduces
both the number of adherent platelets and the extent of
platelet activation on the albumin-adsorbed surface (7). We
have previously shown that serum albumin can be modified
to bear a covalently linked S-NO functional group that
manifests nitrovasodilation and platelet inhibitory proper-
ties (9). More recently, we chemically modified bovine
serum albumin (10) so that the molar ratio of S-NO to
albumin is greater than 1:1. We have shown that this
produces a polynitrosated albumin (pS-NO-BSA) which
can be applied locally to foreign surfaces or to severely
damaged arterial walls to make them less thrombogenic
(11,12). We have also shown that pS-NO-BSA can also be
applied acutely for ten min to angioplastied rabbit femoral
arteries and that this acute local coating significantly reduces
intimal hyperplasia observed 21 days later (10). Thus, we
postulated that pS-NO-BSA might be used to coat glass,
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collagen or P-S stent surfaces and render them less throm-
bogenic. To test this hypothesis, we chose to: 1) study the
extent of platelet adhesion, spreading and aggregation on
uncoated, BSA-coated and pS-NO-BSA-coated glass and
collagen surfaces and 2) test whether or not the coating
would adhere to a metallic stent surface and thereby reduce
platelet activation and attachment to the stent both in vitro
and in situ.
METHODS
Parallel plate chamber experiments. We used an in vitro
parallel plate chamber fitted to an inverted video-enhanced
microscope which permitted us to visualize and video record
the activation of individual platelets on glass and collagen
surfaces (13,14). The parallel-plate chamber was made by
producing a gap (10 mm 3 20 mm 3 120 mm) between a
20 3 20 mm glass cover slip and a 24 3 50 mm glass cover
slip separated by 120 mm thick parafilm (Fig. 1). The 24 3
50 mm glass cover slip was coated with the material to be
exposed to the platelets. Video-enhanced light microscopy
with digital image processing was used to examine platelet
interactions with collagen, collagen coated with BSA and
collagen coated with pS-NO-BSA. The collagen reagent
was obtained from Chrono-log Co. (Harvertown, Pennsyl-
vania). The bovine serum albumin (BSA) was obtained
from Sigma Chemical Co. (St. Louis, Missouri). The
pS-NO-BSA was synthesized in our laboratory as described
below.
Video-enhanced light microscopy. We performed light
microscopy using a modified inverted Nikon Diaphot
equipped with Differential Interference Contrast (DIC)
optics (Fig. 2). A Dage-MTI (Model 65, MK III Series,
Dage-MTI, Inc., Michigan City, Indiana) was attached to
the microscope to produce a video signal of the microscope
image. The video signal was processed by a CVI Model
302-2 Sync Stripper (Colorado Video, Inc., Boulder, Col-
orado) and CVI Model 604 Video Processor (Colorado
Video, Inc., Boulder, Colorado). The time and date were
added to the processed signal by a Panasonic WJ-810
time/date generator (Panasonic Industrial Co., Secaucus,
New Jersey). The final signal was recorded on a Panasonic
NV-9240XD 3⁄40 video recorder (Panasonic Industrial Co.,
Secaucus, New Jersey). For computer image analysis, the
video signal was processed by a FA-210 Digital Time Base
Corrector (For-A Corporation, Japan), and the video image
was processed by Image-1 (Universal Imaging Corporation,
Media, Pennsylvania) hardware and software installed in an
IBM 486-compatible computer.
Platelet preparation. Blood samples were obtained from
adult mongrel dogs by venipuncture using 3.8% trisodium
citrate as the anticoagulant (1 volume citrate to 9 volumes
blood). Platelet-rich plasma (PRP) was prepared by centrif-
Abbreviations and Acronyms
BSA 5 bovine serum albumin
pS-NO-BSA 5 BSA covalently modified to carry
multiple S-NO functional groups
EDRF 5 endothelium-derived relaxing factor
NO 5 nitric oxide
P-S 5 Palmaz-Shatz
PRP 5 platelet rich plasma
TCA 5 trichloroacetic acid
Figure 1. Parallel plate chamber used to visualize platelet attach-
ment and spread over coated glass surfaces using video-enhanced
light microscopy. The parallel-plate chamber was made by pro-
ducing a gap between a (20 3 20 mm) glass cover slip placed on
top of a (24 3 50 mm) glass cover slip separated by parafilm.
Figure 2. Schematic drawing of video-enhanced light microscopy.
A modified inverted Nikon Diaphot equipped with Nomarski
optics. A Dage-MTI (Model 65, MK III Series, Dage-MTI, Inc.,
Michigan City, Indiana) was attached to the microscope to
produce a video signal of the microscope image. The video signal
was processed by a CVI Model 302-2 Sync Stripper (Colorado
Video, Inc., Boulder, Colorado) and CVI Model 604 Video
Processor (Colorado Video, Inc., Boulder, Colorado). The final
signal was recorded on a Panasonic NV-9240XD 3⁄40 video
recorder (Panasonic Industrial Co., Secaucus, New Jersey). The
video image was processed by Image-1 (Universal Imaging Cor-
poration, Media, Pennsylvania) hardware and software which was
installed in a personal computer.
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ugation of whole blood at 165 g for ten min. Platelet-rich
plasma was removed with a polyethylene pipette, and
platelets were separated from plasma proteins by passage
through a Sepharose CL-4B column having a 40-ml total
bead volume. The column was equilibrated with calcium-
free Tyrodes’ buffer, pH 7.4 (136 mM NaCl, 2.7 mM KCl,
0.42 mM NaH2PO4, 12 mM NaHCO3, 1 mM MgCl2, 1 g/l
dextrose, 2 g/l albumin).
Preparation of pS-NO-BSA. Bovine serum albumin co-
valently modified to carry multiple S-NO functional groups
was synthesized as described by Stamler et al. (9). Fatty
acid-free bovine serum albumin (200 mg/ml) was exposed
to a 1.4-molar fold excess of NaNO2 in 0.5 N HCL for
30 min at room temperature and neutralized with an equal
volume of Tris-buffered saline (10 mM Tris [hydroxy-
methyl] aminoethane, pH 7.4 and 150 mM NaCl) and of
0.5 N NaOH. Bovine serum albumin covalently modified to
carry multiple S-NO functional groups was prepared as
previously described and kindly provided by NitroMed, Inc.
(Boston, Massachusetts) (10). The preparation used con-
tained eight moles of NO per mole of albumin.
Platelet surface-activation on collagen. Collagen is a
major constituent of the subendothelial blood vessel wall
and was used to provide a thrombogenic substrate similar to
that of an injured vessel. The bottom (24 3 50 mm) glass
cover slip of the parallel plate chamber was covered with
collagen solution (type I fibrillar collagen from bovine achilles
tendon, Sigma Chemical Co., St. Louis, Missouri). A pipette
tip was used to spread 10 ml of the 25% collagen solution on
three cover slips. The coated slide was set aside for 45 to
60 min to dry and polymerize. One collagen-coated cover slip
was then coated with a 5% solution of BSA (20 ml). Another
collagen-coated cover slip was coated with 0.5 mM of pS-NO-
BSA (20 ml). The third collagen-coated cover slip was used as
a control. After assembling each chamber, 50 ml of platelet
suspension was allowed to fill each chamber by capillary action.
Each chamber was placed on an inverted-stage microscope
(Nikon, DIAPHOT-TMD, Torrance, California). The mi-
croscope was focused on the bottom surface of the chamber to
visualize platelet attachment and spreading over time.
Platelet surface-activation on glass. Before assembling
the parallel-plate chambers, the lower (24 3 50 mm) glass
cover slip was coated with a 5% solution of BSA (20 ml) and
another glass cover slip was coated with 0.5 mM NO of
pS-NO-BSA (20 ml). A third glass cover slip was used as a
control. After assembling each chamber, a 50 ml droplet of
platelet suspension was allowed to fill each chamber by
capillary action. Each chamber was placed on an inverted-
stage microscope (Nikon, DIAPHOT-TMD) to visualize
platelet attachment and spreading on the surface over time.
In vitro effect of a pS-NO-BSA coated versus uncoated
Palmaz-Schatz (P-S) stent on platelet cGMP levels.
Twelve P-S stents were immersed in 1 N HCl for one min
then rinsed in distilled water and allowed to dry. They were
then dip-coated in 800 to 1,000 mM pS-NO-BSA three
times for ten min, followed by ten min of air drying. Five to
seven days later, three coated P-S stents and a control
uncoated stent were rinsed with distilled water and dried.
Each stent was suspended in a polypropylene test tube
containing five ml aliquots of porcine platelet-rich plasma
(PRP) and 100 mM isobutylmethylxanthine for two min. At
the end of the two min periods, the stents were removed and
5 ml of 10% cold trichloroacetic acid (TCA) was immedi-
ately added to the PRP. The mixture of PRP and TCA was
then centrifuged and the supernatant frozen at 270°C for
later analysis of platelet cGMP content.
In vivo effect of a pS-NO-BSA coated versus uncoated
Palmaz-Schatz stent on the deposition of [111In]-labeled
platelets. Six pigs (16–18 kg) were anesthetized with ten
mg/kg ketamine and five mg acepromazine IM after which
20 mg/kg sodium pentobarbital was administered IV. Fifty
milliliters of blood was removed from the pig and autolo-
gous platelets were labeled with [111In]-oxine (15). The
femoral artery and vein were cannulated for arterial pressure
measurement and infusion of the [111In]-labeled platelets.
The right and left carotid arteries were dissected out, and an
electromagnetic flow probe was placed proximally on each
artery. Blood flow was continuously monitored. The autol-
ogous [111In]-labeled platelets were reinjected 30 min prior
to deploying a coated and an uncoated P-S stent in the same
animal. Stents were dip coated as previously described. An
uncoated and a coated P-S stent were placed in the right or
left carotid arteries, respectively, under fluoroscopic guid-
ance using a Sci-Med PTCA NC Cobra 3.0 mm dilation
catheter (Scimed Life Systems Inc., Maple Grove, Minne-
sota). The balloon was inflated to 12 atmospheres for 60 s to
deploy the stents with a repeat inflation after one min for
60 s. The stents were then exposed to flowing blood for two
h. At the end of 2 h of blood perfusion, the pigs were
sacrificed with an overdose of pentobarbital, and the vessels
were harvested and fixed in formaldehyde. The stented
portions of the arteries were placed in the well of an NaI
counter to determine radio-labeled platelet accumulation on
the stent surface. The investigation conforms with the
guidelines for the care and use of laboratory animals by the
US National Institute of Health (NIH publication 1996)
and the University of Wisconsin Research Animal Resource
Center.
Statistics. All data values are reported as mean 6 standard
deviation. The statistical significance of the difference be-
tween measurements is obtained from the paired student t
test and is reported by the p value.
RESULTS
pS-NO-BSA coating of glass. Figure 3 shows photomi-
crographs of platelet adhesion on glass at ten min, BSA
coated glass at 30 min and pS-NO-BSA-coated glass at 30
and 60 min after the platelet suspension was placed on the
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surface. At ten min, all platelets attached to the glass
surface. At 30 min many platelets attached to the BSA-
coated glass and some platelet aggregates formed, while at
30 and 60 min most of the platelets were still unattached to
the pS-NO-BSA-coated glass. The platelets that attached
to the glass and BSA-coated glass surfaces quickly extended
their pseudopods, spread over the surface and caused other
platelets to aggregate. However, the few platelets that
attached to the pS-NO-BSA-coated surface did not spread
over the surface. Figure 4 shows the percent of platelets that
attached to glass, BSA-coated glass and pS-NO-BSA-
coated glass during a 50 min period (the data points
represent averages from four experiments). After 50 min
100% of the platelets attached to the glass surface, and 40 6
15% of the platelets attached to the BSA-coated glass
surface. However, at 50 min, only 14 6 6% of the platelets
attached to the pS-NO-BSA-coated glass surface with the
remaining platelets freely moving (indicating no attachment
or adhesion). This suggests that coating the glass surface
with pS-NO-BSA makes it less thrombogenic than BSA-
coated glass.
pS-NO-BSA coating of collagen. Similar results were
observed for platelet adhesion on collagen, BSA-coated
collagen and pS-NO-BSA-coated collagen. At 30 min,
most of the platelets attached to the BSA-coated collagen
while at 60 min most of the platelets were still unattached to
the pS-NO-BSA-coated collagen. The platelets that at-
tached to collagen and BSA-coated collagen have extended
their pseudopodia along the collagen fibers and spread over
the surface. However, the few platelets that attached to the
pS-NO-BSA-coated collagen did not spread. Figure 5
shows the percentage of platelets that attached to collagen,
Figure 3. Photomicrographs of platelet adhesion on (A) glass at 10 min, (B) BSA-coated glass at 30 min, pS-NO-BSA coated glass at
(C) 30 min and (D) 60 min after the platelet suspension was placed in the parallel plate chamber. At 10 min all the platelets have attached
to the glass surface. At 30 min many platelets have attached to the BSA-coated glass and some platelet aggregates formed, while at 30
and 60 min most of the platelets were still unattached to the pS-NO-BSA-coated collagen. R 5 platelet is round and unattached; D 5
platelet is in dendritic stage with the dendrites attached to the surface; SD 5 platelet is in spread dendritic stage; S 5 platelet is fully spread
over the surface; PA 5 platelet aggregates; RBC 5 red blood cell.
Figure 4. Percent platelet attachment on glass, BSA-coated glass
and pS-NO-BSA-coated glass as a factor of time of platelet
exposure to the surface (n 5 4).
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BSA-coated collagen and pS-NO-BSA-coated collagen
during a 60 min period (the data points are averages from
four experiments). After 30 min, 92 6 13% of the platelets
were attached to the collagen surface, and 79 6 20% of the
platelets were attached to the BSA-coated surface. How-
ever, for the pS-NO-BSA-coated surface at 60 min, only
35 6 24% of the platelets were attached to the collagen
fibers with the remaining platelets floating in the buffered
platelet suspension. This observation demonstrates that
coating the collagen surface with pS-NO-BSA renders it
significantly less thrombogenic compared with BSA-coated
collagen.
Effect of a pS-NO-BSA coating of P-S stents on platelet
cGMP. The average cGMP in the PRP exposed to pS-
NO-BSA coated stents was 5.9 6 0.7 pmoles cGMP/108
platelets, compared with 2.7 6 0.9 pmoles cGMP/108
platelets (p , 0.01, n 5 12) for uncoated stents (Fig. 6).
This observation suggests that the pS-NO-BSA coating did
adhere to the P-S stents and that the NO was available to
dissociate from the coated stents into the platelet rich
plasma and increase platelet cGMP content.
In vivo effect of a pS-NO-BSA coating of P-S stents on
the deposition of [111In]-labeled platelets. Figure 7
shows the gamma counts detected from radiolabeled plate-
lets that attached to the coated and uncoated stents after
being deployed in the carotid arteries of pigs for 2 h. The
average counts were 91,000 6 42,000/min for the coated
stents and 435,000 6 290,000/min for the uncoated stents.
The average platelet accumulation on the uncoated stents
after implantation in pigs with circulating [111In]-labeled
platelets was 4.5 6 1.6-fold higher than the platelet
accumulation on the pS-NO-BSA-coated stents (n 5 6,
p , 0.01).
DISCUSSION
These data suggest that the pS-NO-BSA coating was
significantly more effective than BSA alone in inhibiting
platelet surface activation, adhesion and aggregation on
collagen-coated and glass surfaces. Fifty min after exposure,
all the platelets were attached to the glass and collagen
surfaces. With the albumin coating, most of the platelets
were attached, but with the pS-NO-BSA coating, most of
the platelets were still freely moving on the glass and
collagen surfaces, indicating that they were not surface
activated. This study also demonstrates that a pS-NO-BSA
coating adheres to the P-S stent and that the NO is able to
dissociate from the stent to increase platelet cGMP content.
In addition, this coating significantly reduces the deposition
of autologous [111In]-labeled platelets on stents placed in
pig carotid arteries for two h compared with uncoated stents
placed in pig carotid arteries. This effect is likely due to the
antiadhesive effect of albumin combined with the direct
antiadhesive and antiaggregation effect of NO.
Coating of damaged arterial surfaces with plasma pro-
teins. Artificial surfaces in contact with blood quickly
develop a coating of adsorbed plasma protein that governs
subsequent interaction with blood cells. This initial protein
adsorption occurs within seconds, before the blood platelets
Figure 5. Percent platelet attachment to collagen type I, BSA-
coated collagen and pS-NO-BSA coated collagen as a function of
time (n 5 4).
Figure 6. Cyclic GMP contents of platelets incubated with pS-
NO-BSA-coated and uncoated stents for 2 min in platelet rich
plasma. The average platelet cGMP was 2.9 6 0.7 p moles/108
platelets for the uncoated stents and 5.9 6 0.7 p moles/108
platelets for the pS-NO-BSA-coated stents (p , 0.01, n 5 12).
Figure 7. Platelet accumulation (proportional to gamma counts)
on pS-NO-BSA-coated and uncoated Palmaz-Schatz stents de-
ployed in the carotid arteries of pigs for 2 h. Platelet accumulation
on the uncoated stents was 4.5 6 1.6 fold greater than that on the
pS-NO-BSA-coated stents (p , 0.01, n 5 6).
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and other cellular components reach the surface (16,17).
Much research has focused on the role of the most prevalent
plasma proteins. Albumin is by far the most abundant
protein in serum, and albumin coating has been used to
make synthetic surfaces more thromboresistant (18–20). By
contrast, polymer surfaces coated with fibrinogen, another
abundant protein in serum, promotes platelet activation and
presents a very thrombogenic surface (16). Comparison of
the results of sequential protein adsorption to those of
competitive adsorption from an albumin-fibrinogen mixture
suggests that fibrinogen has a higher binding affinity for
commonly used biopolymer surfaces (16). The initial pro-
tein layer adsorbed to the polymer surface is very important
in determining the thrombogenicity of the surface (17).
Precoating the synthetic surface with albumin renders the
surface less thrombogenic and more blood compatible (16).
In our experiments, coating the glass, collagen and stent
surfaces with nitrosated albumin provided a much more
thromboresistant surface than did coating with albumin
alone. This effect is likely a direct consequence of the
antiplatelet effects of NO.
Mechanisms of platelet inhibition by NO. Both endog-
enous and exogenous NO or NO-donating compounds
inhibit platelet adhesion (21,22) and aggregation (23–25).
Furthermore, NO generating compounds potentiate the
activity of thrombolytic factors to provide further protection
against vascular occlusion (26). The inhibitory response of
platelets is mediated by NO binding to the heme iron of
soluble guanylyl cyclase (GC) which activates the enzyme
and leads to the conversion of magnesium guanosine 59-
triphosphate to guanosine 39,59-monophosphate (cyclic
GMP) (27–29). cGMP regulates receptor-mediated Ca21
influx and mobilization in platelets which are necessary for
platelet activation. The increase in cGMP reduces the
platelet cytosolic calcium concentration (30). It appears that
cGMP is a more potent inhibitor of Ca21 influx than of
Ca21 mobilization in platelets (31).
Among the most stable NO donating compounds are the
S-nitroso-thiols such as S-nitrosated albumin (9).
S-Nitroso-thiols serve as carriers in the mechanism of
action of EDRF by stabilizing the labile NO (9). In the dog,
nitrosated albumin has been shown to inhibit ex vivo
platelet aggregation and significantly prolongs the template
bleeding time (32). Normal endothelial cells are able to
synthesize NO which accounts for the biological properties
of endothelium-derived relaxing factor (EDRF) (33). Nitric
oxide released luminally inhibits the interaction of circulat-
ing platelets with the damaged vessel wall. The capacity of
the endothelium to synthesize NO is reduced in human
coronary atherosclerosis (34). The NO inhibitory effect of
platelets is lost in chronic atherosclerotic lesions and in
acutely induced lesions, such as those caused by balloon
angioplasty. Collagen is a major constituent of the suben-
dothelial blood vessel wall, and collagen type I predominates
in atherosclerotic arterial subendothelium, presenting a very
thrombogenic surface (35). In vitro experiments of flow in a
parallel plate chamber have shown that platelet adhesion is
the result of the adsorption of large vWF multimers onto
collagen and the subsequent binding of platelet GPIb to the
insolubilized vWF (36).
Summary. In conclusion, the S-nitrosated albumin coating
was significantly more potent than an albumin coating in
inhibiting platelet surface activation, adhesion and aggrega-
tion on collagen-coated and glass surfaces. The coating was
also avid for metal stent surfaces and significantly reduced
platelet attachment to the surface during an initial 2 h
perfusion period in vivo. This result is probably due to the
antiadhesive properties of albumin combined with the
antiplatelet effects of NO. By preventing early platelet
attachment and activation to the thrombogenic surface, an
S-nitrosated albumin coating may reduce the incidence of
acute thrombosis and restenosis.
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